Loading...
•
Jun 30, 2024
Iovance Q2 2024 Earnings Report
Iovance reported Q2 2024 earnings with strong Amtagvi launch momentum.
Key Takeaways
Iovance Biotherapeutics reported a revenue of $31.1 million for Q2 2024, driven by the launch of Amtagvi and continued Proleukin sales. The company's cash position as of July 24, 2024, is approximately $449.6 million, expected to fund operations into early 2026.
Total revenue for Q2 2024 was $31.1 million, including Amtagvi and Proleukin sales.
Amtagvi generated $12.8 million in revenue from completed infusions during Q2 2024.
Net loss for Q2 2024 was $97.1 million, or $0.34 per share.
Cash position as of July 24, 2024, was approximately $449.6 million.
Revenue by Segment
Forward Guidance
Iovance anticipates continued growth in Amtagvi demand and expects this growth to continue into 2025, 2026 and beyond. They provided product revenue guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25.
Positive Outlook
- Amtagvi and Proleukin demand remains strong and continues to increase.
- ATC network expansion is expected to accelerate quarterly growth.
- Company is expanding its global commercial footprint.
- Company is expanding its proprietary manufacturing capabilities.
- Company has a broad clinical pipeline.
Challenges Ahead
- Risks related to successful commercialization of products.
- Risks related to market acceptance of products.
- Risks related to ability to manufacture therapies.
- Risks related to timing and ability to develop product candidates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...